Anti-Histamines Improve the Survival of Lung Cancer: a 10-year Cohort Study of Tertiary Hospital in Taiwan.

IF 2.5 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2025-03-28 DOI:10.1159/000545458

Chun-Hsiang Hsu, Chiu-Fan Chen, Chun-Hao Yin, Yao-Shen Chen, Jin-Shuen Chen

{"title":"Anti-Histamines Improve the Survival of Lung Cancer: a 10-year Cohort Study of Tertiary Hospital in Taiwan.","authors":"Chun-Hsiang Hsu, Chiu-Fan Chen, Chun-Hao Yin, Yao-Shen Chen, Jin-Shuen Chen","doi":"10.1159/000545458","DOIUrl":null,"url":null,"abstract":"Introduction: Antihistamines (AHs) have beneficial effects as adjuvant anti-cancer agent in several preclinical and observational studies. We aim to evaluate the effect of AHs on stage IV lung cancer patients.Materials and methods: We used data from the Cancer Registry Database provided by the Cancer Center of Kaohsiung Veterans General Hospital to investigate whether AH use is associated with improved survival among patients with stage IV lung cancer. We analyzed AHs use across various patient subgroups, including sex, age, co-morbidities, co-medications, smoking status, histologic type, treatment modality, and survival time. The primary endpoint was overall survival (OS).Results: A total of 1886 lung cancer patients were enrolled. Of them, 41 (2.1%) patients were AH users, 1845 (97.8%) were AH non-users before lung cancer diagnosis, and 594 (31.6%) patients were AH users, 1292 (68.4%) were AH non-users after lung cancer diagnosis. AH users were more to have comorbidities with hypertension (p <0.001), diabetes mellitus (p <0.001), allergic disease (p <0.001), chronic obstructive pulmonary disease (COPD) (p =0.002), and co-medications with targeted therapy (p <0.001), nonaspirin-NSAID (p <0.001). Pre-diagnostic AH users did not show improved survival outcomes. Post-diagnostic AH users tend to have a better OS among patients with a survival period of more than 90 days (median, 28.4 months and 15.1 months, respectively; HR 0.49; 95% confidence interval 0.43-0.55) Conclusions: AHs use was associated with improved OS in patients with stage IV lung cancer. Further prospective studies are needed to better elucidate the role of AHs in the treatment of lung cancer.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-21"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000545458","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Antihistamines (AHs) have beneficial effects as adjuvant anti-cancer agent in several preclinical and observational studies. We aim to evaluate the effect of AHs on stage IV lung cancer patients.

Materials and methods: We used data from the Cancer Registry Database provided by the Cancer Center of Kaohsiung Veterans General Hospital to investigate whether AH use is associated with improved survival among patients with stage IV lung cancer. We analyzed AHs use across various patient subgroups, including sex, age, co-morbidities, co-medications, smoking status, histologic type, treatment modality, and survival time. The primary endpoint was overall survival (OS).

Results: A total of 1886 lung cancer patients were enrolled. Of them, 41 (2.1%) patients were AH users, 1845 (97.8%) were AH non-users before lung cancer diagnosis, and 594 (31.6%) patients were AH users, 1292 (68.4%) were AH non-users after lung cancer diagnosis. AH users were more to have comorbidities with hypertension (p <0.001), diabetes mellitus (p <0.001), allergic disease (p <0.001), chronic obstructive pulmonary disease (COPD) (p =0.002), and co-medications with targeted therapy (p <0.001), nonaspirin-NSAID (p <0.001). Pre-diagnostic AH users did not show improved survival outcomes. Post-diagnostic AH users tend to have a better OS among patients with a survival period of more than 90 days (median, 28.4 months and 15.1 months, respectively; HR 0.49; 95% confidence interval 0.43-0.55) Conclusions: AHs use was associated with improved OS in patients with stage IV lung cancer. Further prospective studies are needed to better elucidate the role of AHs in the treatment of lung cancer.

查看原文本刊更多论文

导言：在一些临床前和观察性研究中，抗组胺药（AHs）作为辅助抗癌药物具有有益的作用。我们旨在评估抗组胺药对 IV 期肺癌患者的影响：我们利用高雄荣民总医院癌症中心提供的癌症登记数据库数据，研究 AHs 的使用是否与 IV 期肺癌患者生存率的提高相关。我们分析了不同亚组患者使用AHs的情况，包括性别、年龄、合并疾病、合并用药、吸烟状况、组织学类型、治疗方式和生存时间。主要终点是总生存期（OS）：共有1886名肺癌患者入选。其中，41 名（2.1%）患者在确诊肺癌前使用过 AH，1845 名（97.8%）患者未使用过 AH；594 名（31.6%）患者在确诊肺癌后使用过 AH，1292 名（68.4%）患者未使用过 AH。使用 AH 的患者更容易合并高血压（p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.